Company intelligence / Profile preview
DesignMedix
Portland, Oregon, United Statesdesignmedix.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DesignMedix developed small molecule drugs targeting drug-resistant infectious diseases, with a lead antimalarial candidate (DM‑1157) reaching Phase 1 trials before the company ceased operations in March 2020. The pipeline also included another antimalarial series and an antibacterial program for severe diarrheal disease. No recent clinical results are available post-shutdown.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on DesignMedix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DesignMedix.